What Researchers Did
Researchers conducted a retrospective study analyzing data from 49 patients who received hyperbaric oxygen therapy as a primary treatment for sudden deafness.
What They Found
The study found that primary hyperbaric oxygen therapy (HBOT) for sudden deafness led to inferior results compared to standard infusion therapy. Hearing did not change for 63.88% of right ears and 60.98% of left ears, while improvement occurred in 22.49% of right ears and 21.71% of left ears. Overall, neither HBOT nor infusion therapy surpassed the rate of complete spontaneous remission, leading researchers to conclude that primary HBOT for new sudden deafness cannot be recommended.
What This Means for Canadian Patients
For Canadian patients experiencing sudden deafness, this study suggests that hyperbaric oxygen therapy as a first treatment may not be effective. The findings indicate that HBOT did not offer better outcomes than standard care or natural recovery for new cases of sudden deafness. Patients should discuss all available treatment options with their healthcare provider.
Canadian Relevance
The study was not conducted by Canadian authors or in Canada. Sudden deafness is not a Health Canada-recognized indication for hyperbaric oxygen therapy.
Study Limitations
This was a retrospective study, which means it looked back at existing patient data rather than conducting a controlled experiment.